Max Chat
Calendrier des promotions Genenta Science S.p.A.
Calendrier avancé
Graphique simple
À propos de l'entreprise Genenta Science S.p.A.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.Paramètres de base
IPO date
2021-12-15
ISIN
US36870W1009
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
eur
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0 | 0 |
| P/BV | 4.11 | 4 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -47.95 | 0 |
| ROE | -54.13 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | 0 | 10 |
| Debt/Ratio | 0 | 10 |
| Debt/Equity | 0.1863 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 0 | 0 |
| Rentabilité Ebitda, % | 154.8 | 10 |
| Rentabilité EPS, % | 575.04 | 10 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 3.88 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 3.82 $ | 0 $ | 0 $ | 1.56 % | 0 % | 0 % |
| common.calendar.number_days.30d | 4.2 $ | 3.82 $ | 4.36 $ | -7.74 % | 0 % | 0 % |
| common.calendar.number_days.90d | 3.65 $ | 3.49 $ | 4.5 $ | 6.16 % | 0 % | 0 % |
| common.calendar.number_days.180d | 3.83 $ | 3.49 $ | 5.09 $ | 1.17 % | 0 % | 0 % |
| common.calendar.number_days.1y | 4.04 $ | 2.93 $ | 6.92 $ | -4.08 % | 0 % | 0 % |
| common.calendar.number_days.3y | 5.92 $ | 2.55 $ | 7.4 $ | -34.54 % | 0 % | 0 % |
| common.calendar.number_days.5y | 2.55 $ | 2.55 $ | 11.87 $ | 151.96 % | 0 % | 0 % |
| common.calendar.number_days.10y | 2.55 $ | 2.55 $ | 11.87 $ | 151.96 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 3.93 $ | 3.49 $ | 5.09 $ | -1.4 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Dr. Luigi Naldini M.D., Ph.D. | Co-Founder & Chairman of the Executive Scientific Board | N/A | 1959 (66 années) |
| Dr. Bernard Rudolph Gentner M.D., Ph.D. | Co-Founder & Member of the Executive Scientific Board | N/A | 1975 (50 années) |
| Mr. Richard B. Slansky | Chief Financial Officer | N/A | 1958 (67 années) |
| Dr. Carlo Russo M.D. | Chief Medical Officer & Head of Development | N/A | 1953 (72 année) |
| Dr. Stefania Mazzoleni Ph.D. | Director of Program Development | N/A | 1982 (43 année) |
| Ms. Barbara Regonini | Director of Finance | N/A | 1973 (52 année) |
| Mr. Pierluigi Paracchi | Co-Founder, Chairman & CEO | 1973 (52 année) |
Informations sur l'entreprise
Adresse: Italy, Milan, Via Olgettina No. 58 - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.genenta.com
Site web: https://www.genenta.com
